This product is intended for use by trained personnel where required by local regulations. Rapid screening results do not substitute for confirmatory diagnostic testing. Confirm positive or otherwise uncertain results using recommended laboratory methods and follow local public-health reporting and biosafety procedures.
Abbott Determine HIV Early Detect Rapid Card — Product Description
Abbott Determine HIV Early Detect Rapid Card (100-test pack) brings Abbott’s early-detection rapid testing technology to high-volume point-of-care settings. While Abbott also offers single-use early-detect options for at-home screening, this 100-test institutional pack is designed specifically for clinics, hospitals, diagnostic laboratories, and outreach programs that require fast, reliable screening at scale.
The kit delivers rapid visual results in minutes and is engineered for ease of use in diverse settings. It is intended to support early-stage detection workflows by providing timely results that can inform clinical triage, screening programs, and surveillance efforts. Always follow the manufacturer's Instructions For Use (IFU) and local testing algorithms when integrating this test into clinical pathways.
Key Features :
- Early-detection rapid card technology — designed to support earlier identification compared to traditional antibody-only tests (per product claims).
- Bulk institutional pack: 100 tests — ideal for clinics, hospitals, and outreach campaigns requiring high throughput.
- Quick turnaround — results typically available in minutes (refer to IFU for exact read time).
- Simple lateral-flow format with clear visual readout for easy interpretation at point of care.
- Suitable for multiple specimen types (serum, plasma, whole blood) — confirm accepted sample types in the IFU.
- Long shelf life and room-temperature storage (check package for exact storage conditions and expiry).
Important: Rapid tests are screening tools. Results should be interpreted alongside clinical findings and local algorithms. Reactive (positive) or non-reactive (negative) results may require confirmatory laboratory testing (e.g., confirmatory serology or nucleic-acid testing) according to local guidelines. Follow biosafety and specimen-handling procedures and consult the IFU for limitations and performance characteristics.

